Design of a randomized controlled clinical trial assessing dietary sodium restriction and hemodialysis-related symptom profiles
Aim: In hemodialysis patients, the need to have intercurrent sodium and water intake removed by ultrafiltration increases disease burden through the symptoms and signs that occur during hemodialysis (HD). This added burden may be mitigated by reduction of dietary sodium intake. The National Kidney F...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2016-08-01
|
| Series: | Contemporary Clinical Trials Communications |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2451865416300084 |
| _version_ | 1818483916754911232 |
|---|---|
| author | Maya N. Clark-Cutaia Marilyn S. Sommers Emily Anderson Raymond R. Townsend |
| author_facet | Maya N. Clark-Cutaia Marilyn S. Sommers Emily Anderson Raymond R. Townsend |
| author_sort | Maya N. Clark-Cutaia |
| collection | DOAJ |
| description | Aim: In hemodialysis patients, the need to have intercurrent sodium and water intake removed by ultrafiltration increases disease burden through the symptoms and signs that occur during hemodialysis (HD). This added burden may be mitigated by reduction of dietary sodium intake. The National Kidney Foundation (NKF) recommends 2400 mg of dietary sodium daily for patients on HD, and the American Heart Association (AHA) suggests 1500 mg, evidence is lacking, however, to support these recommendations in HD. Moreover, little is known about the relationship of specific levels of dietary sodium intake and the severity of symptoms and signs during ultrafiltration. Our goal will be to determine the effects of carefully-monitored levels of sodium-intake as set forth by the NKF and AHA on symptoms and signs in patients undergoing (HD).
Methods: We designed a three-group (2400 mg, 1500 mg, unrestricted), double blinded randomized controlled trial with a sample of 42 HD participants to determine whether 1. Symptom profiles and interdialytic weight gains vary among three sodium intake groups; 2. The effect of HD-specific variables on the symptom profiles among the three groups and 3. Whether total body water extracellular volume and intracellular volume measured with bioimpedance varies across the three groups. We will also examine the feasibility of recruitment, enrollment, and retention of participants for the five-day inpatient stay.
Conclusion: Curbing dietary sodium intake may lead to improvement in intradialytic symptom amelioration and potential for better long-term outcomes. Generating empirical support will be critical to ascertain, and espouse, the appropriate level of sodium intake for patients receiving HD. |
| first_indexed | 2024-12-10T15:48:19Z |
| format | Article |
| id | doaj.art-18ed8a6530e3430b970b001a13414a6d |
| institution | Directory Open Access Journal |
| issn | 2451-8654 |
| language | English |
| last_indexed | 2024-12-10T15:48:19Z |
| publishDate | 2016-08-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Contemporary Clinical Trials Communications |
| spelling | doaj.art-18ed8a6530e3430b970b001a13414a6d2022-12-22T01:42:53ZengElsevierContemporary Clinical Trials Communications2451-86542016-08-013C707310.1016/j.conctc.2016.04.002Design of a randomized controlled clinical trial assessing dietary sodium restriction and hemodialysis-related symptom profilesMaya N. Clark-Cutaia0Marilyn S. Sommers1Emily Anderson2Raymond R. Townsend3University of Pennsylvania School of Nursing, 418 Curie Blvd, Philadelphia, PA 19104, United StatesUniversity of Pennsylvania School of Nursing, 418 Curie Blvd, Philadelphia, PA 19104, United StatesUniversity of Pennsylvania School of Nursing, 418 Curie Blvd, Philadelphia, PA 19104, United StatesUniversity of Pennsylvania Perelman School of Medicine, 1 Founders Bldg, 3400 Spruce Street, Philadelphia, PA 19104, United StatesAim: In hemodialysis patients, the need to have intercurrent sodium and water intake removed by ultrafiltration increases disease burden through the symptoms and signs that occur during hemodialysis (HD). This added burden may be mitigated by reduction of dietary sodium intake. The National Kidney Foundation (NKF) recommends 2400 mg of dietary sodium daily for patients on HD, and the American Heart Association (AHA) suggests 1500 mg, evidence is lacking, however, to support these recommendations in HD. Moreover, little is known about the relationship of specific levels of dietary sodium intake and the severity of symptoms and signs during ultrafiltration. Our goal will be to determine the effects of carefully-monitored levels of sodium-intake as set forth by the NKF and AHA on symptoms and signs in patients undergoing (HD). Methods: We designed a three-group (2400 mg, 1500 mg, unrestricted), double blinded randomized controlled trial with a sample of 42 HD participants to determine whether 1. Symptom profiles and interdialytic weight gains vary among three sodium intake groups; 2. The effect of HD-specific variables on the symptom profiles among the three groups and 3. Whether total body water extracellular volume and intracellular volume measured with bioimpedance varies across the three groups. We will also examine the feasibility of recruitment, enrollment, and retention of participants for the five-day inpatient stay. Conclusion: Curbing dietary sodium intake may lead to improvement in intradialytic symptom amelioration and potential for better long-term outcomes. Generating empirical support will be critical to ascertain, and espouse, the appropriate level of sodium intake for patients receiving HD.http://www.sciencedirect.com/science/article/pii/S2451865416300084DietKidney failureChronicHypertrophyLeft ventricularRenal dialysisSodium |
| spellingShingle | Maya N. Clark-Cutaia Marilyn S. Sommers Emily Anderson Raymond R. Townsend Design of a randomized controlled clinical trial assessing dietary sodium restriction and hemodialysis-related symptom profiles Contemporary Clinical Trials Communications Diet Kidney failure Chronic Hypertrophy Left ventricular Renal dialysis Sodium |
| title | Design of a randomized controlled clinical trial assessing dietary sodium restriction and hemodialysis-related symptom profiles |
| title_full | Design of a randomized controlled clinical trial assessing dietary sodium restriction and hemodialysis-related symptom profiles |
| title_fullStr | Design of a randomized controlled clinical trial assessing dietary sodium restriction and hemodialysis-related symptom profiles |
| title_full_unstemmed | Design of a randomized controlled clinical trial assessing dietary sodium restriction and hemodialysis-related symptom profiles |
| title_short | Design of a randomized controlled clinical trial assessing dietary sodium restriction and hemodialysis-related symptom profiles |
| title_sort | design of a randomized controlled clinical trial assessing dietary sodium restriction and hemodialysis related symptom profiles |
| topic | Diet Kidney failure Chronic Hypertrophy Left ventricular Renal dialysis Sodium |
| url | http://www.sciencedirect.com/science/article/pii/S2451865416300084 |
| work_keys_str_mv | AT mayanclarkcutaia designofarandomizedcontrolledclinicaltrialassessingdietarysodiumrestrictionandhemodialysisrelatedsymptomprofiles AT marilynssommers designofarandomizedcontrolledclinicaltrialassessingdietarysodiumrestrictionandhemodialysisrelatedsymptomprofiles AT emilyanderson designofarandomizedcontrolledclinicaltrialassessingdietarysodiumrestrictionandhemodialysisrelatedsymptomprofiles AT raymondrtownsend designofarandomizedcontrolledclinicaltrialassessingdietarysodiumrestrictionandhemodialysisrelatedsymptomprofiles |